-
-
-
-
-
-
-
Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone
-
-
-
-
-
-
-
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
-
-
-
-
-
-
-
Aptevo reports 86% clinical benefit rate for AML drug mipletamig
-
-
-
-
-
-
-
Aptevo Therapeutics announces 1-for-18 reverse stock split
-
-
-
-
-
-
-
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
-
-
-
-
-
-
-
Aptevo highlights preclinical prostate cancer therapy candidate
-
-
-
-
-
-
-
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
-
454,888 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

